Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2024Journal of Clinical Oncology

Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMarta LasaNavarre Institute of Health ResearchLNLaura NotarfranchiAzienda Usl Toscana CentroCACristina AgullóUniversidad de Salamanca

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lasa et al. (2024) studied this question.

synapsesocial.com/papers/68e5600ee2b3180350efd4ebhttps://doi.org/10.1200/jco.24.00635
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials2022 · 62 citations
  2. 2Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma2023 · 40 citations
  3. 3Don’t let the genie out of the bottle!2024 · 6 citations
  4. 4EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma2024 · 130 citations
  5. 5Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk2022 · 90 citations